Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 17/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.39 |
| ▸ | DRD2 | P14416 | 14/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480593 | 0.81 | DRD3 (0.40) | DRD3KCNH2DRD2CYP2D6CHRM1 | |
| SCHEMBL13895695 | 0.76 | DRD3 (0.39) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL8021753 | 0.71 | IMPDH2 (0.39) | — | |
| SCHEMBL17712879 | 0.69 | DRD3 (0.55) | DRD3KCNH2DRD2CHRM1CHRM3 | |
| SCHEMBL11911777 | 0.69 | DRD2 (0.30) | DRD3KCNH2DRD2 | |
| SCHEMBL25436203 | 0.69 | DRD3 (0.31) | DRD3KCNH2DRD2CHRM1CHRM3 | |
| SCHEMBL378667 | 0.68 | DRD3 (0.60) | DRD3KCNH2DRD2CYP2D6CHRM1 | |
| SCHEMBL17725475 | 0.67 | DRD3 (0.59) | DRD3KCNH2DRD2CYP2D6CHRM1 | |
| SCHEMBL17713118 | 0.67 | DRD3 (0.47) | DRD3KCNH2DRD2CHRM1CHRM3 | |
| SCHEMBL14557028 | 0.66 | HSD11B1 (0.34) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-107108597-B | Dopamine D3 receptor antagonist compounds | 英立维尔英国有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | INDIVIOR UK LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-7838680-B2 | Process for preparing heterocyclic derivatives | GLAXO GROUP LIMITED (GB) | 2010-11-23 | — | — | US | disclosed |
| US-20100048895-A1 | Process for Preparing Heterocyclic Derivatives | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048895-A1 | Process for Preparing Heterocyclic Derivatives | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080058398-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20080058398-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20070232808-A1 | PROCESS FOR PREPARING HETEROCYCLIC DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232808-A1 | PROCESS FOR PREPARING HETEROCYCLIC DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| EP-1737851-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | GLAXO GROUP LIMITED (GB) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005087764-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058398-A1 | Compounds | TPMT, PPP4C, SLCO4C1 | DRD3 2001/4885KCNH2 1730/4885DRD2 3033/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | DRD3 1/4885KCNH2 1283/4885DRD2 2/4885 |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | DRD3, DRD2, SLC6A3 | DRD3 1/4885KCNH2 399/4885DRD2 2/4885 |
| US-20100048895-A1 | Process for Preparing Heterocyclic Derivatives | HCAR3, CBR3, HRH4 | DRD3 97/4885KCNH2 1038/4885DRD2 215/4885 |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | DRD3, DRD2, SLC6A3 | DRD3 1/4885KCNH2 1888/4885DRD2 2/4885 |
| US-20070232808-A1 | PROCESS FOR PREPARING HETEROCYCLIC DERIVATIVES | HCAR3, CBR3, NR4A3 | DRD3 95/4885KCNH2 891/4885DRD2 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.